About the Company
Clinical Trials & Published Papers

The AMES Rehab Therapy Medical Device with a Food and Drug Administration (FDA) 510(k) Class II clearance to market and sell to hospitals and rehabilitation clinics, is currently being operated in a limited number of hospitals to treat persons whose movement is severely limited as a result of diseases of and injuries to the brain and spinal cord.

Typically, this population would be experiencing a stroke, acquired brain injury, or incomplete spinal cord injury (iSCI).

A 510(k) Class II Clearance from the FDA, to market and sell the AMES R300 Rehab Therapy Device, was received on May 24, 2013.